UBRELVY® (ubrogepant) tablets 50mg 100mg

ACUTE CARE PATH REDEFINED

RSVP FOR A LIVE EVENT with your peers to discuss the phases of a migraine attack and UBRELVY clinical and real-world evidence data.

PRESENTED BY:

Laurel Short, APN
Family Nurse Practitioner
Sunflower Medical Group
Roeland Park KS

Tuesday, January 13, 2026 at 5:30 PM CT

Ocean Zen Pacific Rim
4117 South National Avenue, Springfield, MO 65807

Please RSVP using the link or QR code at left:
https://migrainelive.com/register/235734
Contact your AbbVie Representative with questions
Alissa Blackman
Phone: 4177737161 Email:
alissa.blackman@abbvie.com

INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

UBRELVY is contraindicated:

- With concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).
- In patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

Hypertension (HTN): Development or worsening of pre-existing HTN has been reported following the use of CGRP antagonists, including UBRELVY. Some patients who developed new-onset HTN had risk factors. There were cases requiring initiation of HTN treatment and, in some cases, hospitalization. HTN may occur at any time but was most frequently reported within 7 days of initiation. The CGRP antagonist was discontinued in many of the cases. Monitor patients for new-onset or worsening of pre-existing HTN and consider whether discontinuation of UBRELVY is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Raynaud's phenomenon (RP): Development, recurrence, or worsening of pre-existing RP has been reported following the use of CGRP antagonists, including UBRELVY. In cases with small molecule CGRP antagonists, symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms. UBRELVY should be discontinued if signs or symptoms of RP develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of RP should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

DRUG INTERACTIONS

- Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
- Dose modifications are recommended when using the following:
  - Moderate or weak CYP3A4 inhibitors and inducers
  - BCRP and/or P-gp only inhibitors

Please see accompanying full Prescribing Information or visit https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf.

This promotional event is brought to you by AbbVie and is not certified for continuing medical education.

The speaker is a paid consultant presenting on behalf of AbbVie and the information being presented is consistent with FDA guidelines. This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. It is AbbVie's policy to include only those healthcare professionals involved in patient care consistent with our product indication(s). The cost of meals and refreshments provided to U.S. HCPs may be subject to public disclosure. AbbVie's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. AbbVie abides by applicable federal and state laws, which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from AbbVie. Please comply with applicable law.

US-UBR-250296 09/25

abbvie